INS and type 2 diabetes mellitus: Considering that the pathophysiology of type 2 diabetes involves a decrease in insulin secretion secondary to decreased β cell mass and function, and inappropriate hyperglucagonemia, the reprogramming of α cells into insulin-secreting cells seems to be an appealing treatment for this disorder by restoring β cell mass, leading to increased insulin secretion, and by decreasing α cell mass with a potential reduction in the hyperglucagonemia and insulin resistance.